JP2005500304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500304A5 JP2005500304A5 JP2003506470A JP2003506470A JP2005500304A5 JP 2005500304 A5 JP2005500304 A5 JP 2005500304A5 JP 2003506470 A JP2003506470 A JP 2003506470A JP 2003506470 A JP2003506470 A JP 2003506470A JP 2005500304 A5 JP2005500304 A5 JP 2005500304A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- protein
- antibody
- particle
- spherical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 100
- 108091007433 antigens Proteins 0.000 claims 100
- 102000036639 antigens Human genes 0.000 claims 100
- 239000002245 particle Substances 0.000 claims 93
- 102000034238 globular proteins Human genes 0.000 claims 83
- 108091005896 globular proteins Proteins 0.000 claims 83
- 108090000623 proteins and genes Proteins 0.000 claims 39
- 235000018102 proteins Nutrition 0.000 claims 38
- 102000004169 proteins and genes Human genes 0.000 claims 38
- 239000000203 mixture Substances 0.000 claims 37
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 18
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 238000002405 diagnostic procedure Methods 0.000 claims 15
- 239000000243 solution Substances 0.000 claims 11
- 238000009007 Diagnostic Kit Methods 0.000 claims 10
- 239000000725 suspension Substances 0.000 claims 10
- 230000004071 biological effect Effects 0.000 claims 9
- 241000701022 Cytomegalovirus Species 0.000 claims 8
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 8
- 241000711549 Hepacivirus C Species 0.000 claims 8
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 8
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 8
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 8
- 230000003612 virological effect Effects 0.000 claims 8
- 235000004252 protein component Nutrition 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 5
- 239000002159 nanocrystal Substances 0.000 claims 5
- 241000709687 Coxsackievirus Species 0.000 claims 4
- 241000709661 Enterovirus Species 0.000 claims 4
- 241000991587 Enterovirus C Species 0.000 claims 4
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 241000700721 Hepatitis B virus Species 0.000 claims 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 4
- 241000701806 Human papillomavirus Species 0.000 claims 4
- 208000000389 T-cell leukemia Diseases 0.000 claims 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 4
- 239000000872 buffer Substances 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 241000701161 unidentified adenovirus Species 0.000 claims 4
- 241000712461 unidentified influenza virus Species 0.000 claims 4
- 108091061980 Spherical nucleic acid Proteins 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 238000002983 circular dichroism Methods 0.000 claims 3
- 239000011246 composite particle Substances 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 3
- 239000012460 protein solution Substances 0.000 claims 3
- 108010088751 Albumins Chemical class 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 229920002678 cellulose Chemical class 0.000 claims 2
- 239000001913 cellulose Chemical class 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 238000004611 spectroscopical analysis Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 229920001651 Cyanoacrylate Polymers 0.000 claims 1
- 108010002156 Depsipeptides Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 229960000446 abciximab Drugs 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 229920000615 alginic acid Chemical class 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 230000036436 anti-hiv Effects 0.000 claims 1
- 230000003622 anti-hsv Effects 0.000 claims 1
- -1 antibodies Proteins 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 239000012148 binding buffer Substances 0.000 claims 1
- 229920000249 biocompatible polymer Polymers 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012149 elution buffer Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229940014259 gelatin Drugs 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 1
- 239000000832 lactitol Substances 0.000 claims 1
- 229960003451 lactitol Drugs 0.000 claims 1
- 235000010448 lactitol Nutrition 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- ZTUGCJNAJJDKDC-UHFFFAOYSA-N n-(3-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCO ZTUGCJNAJJDKDC-UHFFFAOYSA-N 0.000 claims 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000000962 organic group Chemical group 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920000117 poly(dioxanone) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000011363 radioimmunotherapy Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29998901P | 2001-06-21 | 2001-06-21 | |
| PCT/US2002/019870 WO2003000014A2 (en) | 2001-06-21 | 2002-06-21 | Spherical protein particles and methods of making and using them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005500304A JP2005500304A (ja) | 2005-01-06 |
| JP2005500304A5 true JP2005500304A5 (https=) | 2005-11-17 |
Family
ID=23157185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506470A Pending JP2005500304A (ja) | 2001-06-21 | 2002-06-21 | 球状タンパク質粒子およびそれらの作製方法および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7998477B2 (https=) |
| EP (1) | EP1492554B1 (https=) |
| JP (1) | JP2005500304A (https=) |
| AU (1) | AU2002322295C1 (https=) |
| CA (1) | CA2451185A1 (https=) |
| IL (1) | IL159475A0 (https=) |
| NZ (1) | NZ530700A (https=) |
| WO (1) | WO2003000014A2 (https=) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ526720A (en) * | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
| CA2451185A1 (en) | 2001-06-21 | 2003-01-03 | Altus Biologics, Inc. | Spherical protein particles and methods of making and using them |
| JP4161101B2 (ja) * | 2002-06-21 | 2008-10-08 | 独立行政法人 日本原子力研究開発機構 | 生体高分子の結晶育成装置 |
| RU2426590C2 (ru) | 2003-07-18 | 2011-08-20 | Бакстер Интернэшнл Инк. | Способы изготовления, применение и композиции небольших сферических частиц, приготовленных регулируемым фазовым разделением |
| JP2005241389A (ja) * | 2004-02-25 | 2005-09-08 | Ochiyanomizu Jiyoshi Univ | 蛍光標識糖鎖の特異的固定化試薬および固定化方法 |
| US8333995B2 (en) | 2004-05-12 | 2012-12-18 | Baxter International, Inc. | Protein microspheres having injectable properties at high concentrations |
| DK2072040T3 (da) | 2004-05-12 | 2013-07-29 | Baxter Healthcare Sa | Terapeutisk anvendelse af nukleinsyremikrokugler |
| US8728525B2 (en) | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
| WO2005112885A2 (en) | 2004-05-12 | 2005-12-01 | Baxter International Inc. | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
| JP5553963B2 (ja) | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
| ES2390354T3 (es) * | 2005-07-22 | 2012-11-12 | Amgen, Inc | Liofilizados de proteínas concentrados, procedimientos y usos |
| DK1948259T3 (en) * | 2005-10-26 | 2017-04-10 | Genesis Tech Ltd | ACELLULAR BIOabsorbable Tissue Regeneration Matrices Produced by Incubation of ACELLULAR BLOOD PRODUCTS |
| JP5147699B2 (ja) * | 2005-12-20 | 2013-02-20 | 富士フイルム株式会社 | タンパク質ナノ粒子およびその使用 |
| CN101415395B (zh) | 2006-03-29 | 2012-02-08 | 富士胶片株式会社 | 酪蛋白纳米粒子 |
| JP5118139B2 (ja) | 2006-08-04 | 2013-01-16 | バクスター・インターナショナル・インコーポレイテッド | 新規発症自己免疫性糖尿病を予防および／または逆転させるためのマイクロスフィアに基づく組成物 |
| US20080299182A1 (en) * | 2007-03-01 | 2008-12-04 | Shuyuan Zhang | Methods and formulations for topical gene therapy |
| CN101686939B (zh) | 2007-04-17 | 2013-03-27 | 巴克斯特国际公司 | 用于肺部投送的核酸微粒 |
| JP2008285432A (ja) | 2007-05-16 | 2008-11-27 | Fujifilm Corp | 皮膚外用剤 |
| EP2170283B1 (en) | 2007-06-22 | 2019-01-09 | Board of Regents, The University of Texas System | Formation of stable submicron peptide or protein particles by thin film freezing |
| WO2009005709A1 (en) * | 2007-06-28 | 2009-01-08 | Surmodics, Inc. | Polypeptide microparticles |
| WO2009005718A1 (en) * | 2007-06-28 | 2009-01-08 | Surmodics, Inc. | Polypeptide microparticles having sustained release characteristics, methods and uses |
| KR100845009B1 (ko) * | 2007-08-07 | 2008-07-08 | 한국생명공학연구원 | 전하를 띠는 물질이 고착된 다공성 고분자 입자 및 그제조방법 |
| JP2012501965A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
| ES2721850T3 (es) | 2008-06-16 | 2019-08-05 | Pfizer | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas |
| US8613951B2 (en) * | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| US8323685B2 (en) * | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US8367427B2 (en) | 2008-08-20 | 2013-02-05 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US8323615B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing multi-phasic dispersions |
| EP2376522A4 (en) * | 2008-11-16 | 2013-12-25 | Univ Texas | LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS |
| FR2938542B1 (fr) * | 2008-11-18 | 2013-06-14 | Sang Bourgogne Franche Comte Ets Franc | Proteine cd20 tronquee, deltacd20 |
| WO2010068866A2 (en) * | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| US20100216804A1 (en) * | 2008-12-15 | 2010-08-26 | Zale Stephen E | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
| US8529933B2 (en) | 2009-07-27 | 2013-09-10 | Warsaw Orthopedic, Inc. | Biphasic calcium phosphate cement for drug delivery |
| JP5491119B2 (ja) | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | 薬物含有微粒子を含む医薬組成物およびその製造方法 |
| US8357401B2 (en) | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
| ES2780156T3 (es) | 2009-12-15 | 2020-08-24 | Pfizer | Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular |
| US20120309016A1 (en) * | 2010-02-11 | 2012-12-06 | Hoffmann-La Roche Inc. | 3d adcc nk facs assay |
| US9643996B2 (en) * | 2011-11-04 | 2017-05-09 | Battelle Memorial Institute | Processes for producing protein microparticles |
| PL3574897T3 (pl) | 2011-11-18 | 2022-05-09 | Regeneron Pharmaceuticals, Inc. | Postać użytkowa o przedłużonym uwalnianiu zawierająca mikrocząstki białka polimerowego do stosowania w ciele szklistym oka w leczeniu naczyniowych zaburzeń oczu |
| US20150177115A1 (en) | 2012-04-06 | 2015-06-25 | Slingshot Biosciences | Hydrogel particles with tunable optical properties |
| ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
| MX356097B (es) | 2012-09-17 | 2018-05-14 | Pfizer Inc Star | Proceso para la preparacion de nanoparticulas terapeuticas. |
| JP6026002B2 (ja) * | 2012-11-27 | 2016-11-16 | アルテオジェン インコーポレイテッド | タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CN103018446B (zh) * | 2012-12-24 | 2014-08-20 | 青岛汉唐生物科技有限公司 | 用于检测甲型肝炎病毒抗体的方法、检测用的试剂盒及其制备方法 |
| RU2016111112A (ru) * | 2013-08-26 | 2017-09-29 | ПиЭс ТЕРЭПИС ЛТД. | Композиции и способы для лечения патологических состояний носа |
| WO2015058173A1 (en) * | 2013-10-18 | 2015-04-23 | Abbvie Inc. | Stable solid units and methods of making the same |
| MA39734B1 (fr) | 2014-03-14 | 2019-07-31 | Pfizer | Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation |
| CN106535928A (zh) | 2014-07-18 | 2017-03-22 | 般财团法人化学及血清疗法研究所 | 包含类病毒颗粒的疫苗 |
| JP6910949B2 (ja) * | 2014-08-14 | 2021-07-28 | ブラウン ユニバーシティ | タンパク質を安定化させ、送達するための組成物 |
| US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
| EP3256850B1 (en) | 2015-02-09 | 2025-07-09 | Slingshot Biosciences, Inc. | Hydrogel particles with tunable optical properties and methods for using the same |
| AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
| AU2016252393A1 (en) | 2015-04-24 | 2017-11-09 | Colgate-Palmolive Company | Porous protein particles as carriers for actives |
| US10281400B2 (en) * | 2015-07-13 | 2019-05-07 | Sony Corporation | Method for enhancing luminescence, substance detection method, substance detection apparatus, and luminescence enhancer |
| WO2017219974A1 (zh) | 2016-06-22 | 2017-12-28 | 本康生物制药（深圳）有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
| CN108504638B (zh) * | 2017-02-28 | 2021-09-17 | 中国科学院过程工程研究所 | 一种口蹄疫灭活病毒抗原纯化或储存的方法 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| CN108398550B (zh) * | 2018-03-07 | 2022-07-26 | 深圳市伯劳特生物制品有限公司 | 一种组合物、芯片及其制备方法和包含有该芯片的检测装置 |
| KR102885113B1 (ko) | 2018-10-18 | 2025-11-13 | 머크 샤프 앤드 돔 엘엘씨 | 항-rsv 항체의 제제 및 그의 사용 방법 |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| CN117100683A (zh) * | 2018-12-31 | 2023-11-24 | 拉尼医疗有限公司 | 使用可吞服药物递送装置递送到肠道内腔的治疗剂制剂 |
| US10993459B2 (en) | 2019-09-23 | 2021-05-04 | Ralph Yoder | Method for unlocking bioactive proteins |
| WO2021108548A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| JP7759328B2 (ja) | 2020-01-24 | 2025-10-23 | スリングショット バイオサイエンシーズ， インコーポレイテッド | 細胞様較正粒子のための組成物および方法 |
| US20230088835A1 (en) * | 2020-03-02 | 2023-03-23 | Northwestern University | Fit-flares for detection of intracellular analytes in live cells |
| CA3177834A1 (en) | 2020-05-04 | 2021-11-11 | Jeffrey Kim | Compositions and methods for passive optical barcoding for multiplexed assays |
| WO2022115588A1 (en) | 2020-11-25 | 2022-06-02 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| JP2024500409A (ja) | 2020-12-17 | 2024-01-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質封入マイクロゲルの作製 |
| JP2024539956A (ja) | 2021-10-29 | 2024-10-31 | スリングショット バイオサイエンシーズ， インコーポレイテッド | フィーダー細胞としておよび合成抗原提示細胞としてのヒドロゲル粒子 |
| CN114460301B (zh) * | 2021-12-28 | 2024-11-29 | 上海睿康生物科技有限公司 | 一种测定血清中肌酸激酶同工酶含量的检测试剂盒 |
| CN119907921A (zh) | 2022-05-05 | 2025-04-29 | 弹弓生物科学公司 | 用于血液学的作为红细胞模拟物的工程化颗粒和含有工程化颗粒的组合物 |
| AU2023280490A1 (en) | 2022-06-02 | 2024-12-05 | Slingshot Biosciences, Inc. | Apoptotic cell mimic |
| EP4608872A2 (en) | 2022-10-26 | 2025-09-03 | Slingshot Biosciences, Inc. | Size-tunable synthetic particles with tunable optical properties and methods for using the same for immune cell activation |
| WO2025049609A1 (en) | 2023-08-29 | 2025-03-06 | Slingshot Biosciences, Inc. | Cd34 stem cell mimics |
| CN119925588B (zh) * | 2025-04-08 | 2025-07-01 | 北京华诺泰生物医药科技有限公司 | 基于gE/pORF7双抗原纳米晶与智能相变佐剂的重组带状疱疹疫苗 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4334024A (en) | 1980-11-03 | 1982-06-08 | Sarjit Johal | Preparation and crystallization of fraction I protein from plant sources |
| DE3327709A1 (de) | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
| DE3419782C1 (de) | 1984-05-26 | 1985-11-14 | Gödecke AG, 1000 Berlin | Sphaerische Proteinpartikel mit immunadsorbierenden Eigenschaften und Verfahren zu deren Herstellung |
| US6727278B1 (en) * | 1986-08-27 | 2004-04-27 | Dms Pharmaceutical Inc. | Pharmaceutically active agents that impede amyloid formation in vivo |
| WO1991009943A1 (en) | 1989-12-21 | 1991-07-11 | Novo Nordisk A/S | Method for crystallization of enzymes |
| US5780599A (en) | 1990-07-13 | 1998-07-14 | Novo Nordisk A/S | Growth hormone crystals and a process for production of growth hormone crystals |
| US5618710A (en) | 1990-08-03 | 1997-04-08 | Vertex Pharmaceuticals, Inc. | Crosslinked enzyme crystals |
| US6063910A (en) * | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
| US5751453A (en) * | 1991-12-06 | 1998-05-12 | Ncr Corporation | Liquid crystal display with pen-input capability |
| EP0646000A4 (en) * | 1992-11-16 | 1997-05-02 | Univ Mercer | COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES. |
| US6794357B1 (en) * | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
| US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
| JPH11510061A (ja) | 1995-08-30 | 1999-09-07 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 結晶性ｚａｐファミリータンパク質 |
| US5972331A (en) | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
| US6652837B1 (en) * | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
| US5932212A (en) | 1996-05-24 | 1999-08-03 | Altus Biologics, Inc. | Crosslinked protein crystal formulations and their use as catalysts in organic solvents |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6310038B1 (en) | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
| US6140475A (en) | 1997-04-11 | 2000-10-31 | Altus Biologics Inc. | Controlled dissolution crosslinked protein crystals |
| EP2311436A1 (en) * | 1998-04-27 | 2011-04-20 | Altus Pharmaceuticals Inc. | Stabilized protein crystals, formulations containing them and methods of making them |
| US6956021B1 (en) * | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| NZ513163A (en) | 1999-03-05 | 2004-02-27 | Genencor Int | Method for rapidly obtaining crystals with desirable morphologies |
| ATE555773T1 (de) * | 1999-06-09 | 2012-05-15 | Sievers Robert E | Überkritische fluidgestützte verneblung und blasen trochnen |
| WO2000077281A1 (en) | 1999-06-10 | 2000-12-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Encapsulation of crystals via multilayer coatings |
| GB9915975D0 (en) * | 1999-07-07 | 1999-09-08 | Bradford Particle Design Ltd | Method for the formation of particles |
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| FR2802445B1 (fr) * | 1999-12-15 | 2002-02-15 | Separex Sa | Procede et dispositif de captage de fines particules par piegeage au sein d'un melange solide de type neige carbonique |
| US6562952B1 (en) * | 2000-10-31 | 2003-05-13 | The University Of Kansas | Precipitation of proteins from organic solutions |
| US6756062B2 (en) * | 2000-11-03 | 2004-06-29 | Board Of Regents University Of Texas System | Preparation of drug particles using evaporation precipitation into aqueous solutions |
| EP1801123A3 (en) * | 2000-12-28 | 2007-11-21 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| NZ526720A (en) * | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
| CA2451185A1 (en) | 2001-06-21 | 2003-01-03 | Altus Biologics, Inc. | Spherical protein particles and methods of making and using them |
| US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
-
2002
- 2002-06-21 CA CA002451185A patent/CA2451185A1/en not_active Abandoned
- 2002-06-21 AU AU2002322295A patent/AU2002322295C1/en not_active Ceased
- 2002-06-21 WO PCT/US2002/019870 patent/WO2003000014A2/en not_active Ceased
- 2002-06-21 EP EP02756275.0A patent/EP1492554B1/en not_active Expired - Lifetime
- 2002-06-21 IL IL15947502A patent/IL159475A0/xx unknown
- 2002-06-21 JP JP2003506470A patent/JP2005500304A/ja active Pending
- 2002-06-21 NZ NZ530700A patent/NZ530700A/en not_active IP Right Cessation
-
2003
- 2003-12-19 US US10/741,861 patent/US7998477B2/en not_active Expired - Fee Related
-
2011
- 2011-07-27 US US13/192,345 patent/US20120282464A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005500304A5 (https=) | ||
| AU2002322295C1 (en) | Spherical protein particles and methods of making and using them | |
| RU2442571C2 (ru) | Кристаллизация антител или их фрагментов | |
| Akash et al. | Development of therapeutic proteins: advances and challenges | |
| AU2002322295A1 (en) | Spherical protein particles and methods of making and using them | |
| JP2018535650A (ja) | Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用 | |
| JPH04505010A (ja) | 免疫調節障害の処置のための薬剤生成物 | |
| KR20160062760A (ko) | 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도 | |
| JPH06502410A (ja) | 二特異的試薬を用いた標的免疫化 | |
| JPH0717519B2 (ja) | α―インターフェロンに対する抗体と複合されたα―インターフェロン治療製剤 | |
| TW201223541A (en) | Liquid formulations of long acting interferon alpha conjugate | |
| JP2001513335A (ja) | 細胞内の物質移送のための抗体から誘導されたベクター | |
| JP2004534513A5 (https=) | ||
| WO2018121578A1 (zh) | 稳定的包含cd147单克隆抗体的药物制剂 | |
| US20250295590A1 (en) | Fabrication of protein-encapsulating microgels | |
| US20170051058A1 (en) | Immunostimulatory anti-ceacam1 antibody | |
| JP2019536756A (ja) | Ｉｌ−２３ａ抗体を用いて疾患を処置する方法 | |
| Tite et al. | Inverse Ir gene control of the antibody and T cell proliferative responses to human basement membrane collagen. | |
| CN113444180B (zh) | 靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用 | |
| JP2004514423A5 (https=) | ||
| WO1994028879A1 (en) | Oral pharmaceutical compositions comprising a protein or peptide, an antibody and polymeric beads | |
| CN101177453B (zh) | 抗人肿瘤坏死因子α的重组嵌合抗体 | |
| CN101111227A (zh) | 产生可生物再吸收微颗粒的方法,由此得到的微颗粒以及其应用 | |
| WO2022048494A1 (en) | Anti-sars-cov-2 neutralizing antibodies | |
| CN115569191A (zh) | 一种重组人源化抗bcma/cd3双特异性抗体冻干制剂 |